These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38621403)

  • 21. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
    Lammers A; Wang R; Cetnar J; Prasad V
    Blood Cancer J; 2017 Nov; 7(12):637. PubMed ID: 29187747
    [No Abstract]   [Full Text] [Related]  

  • 22. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 23. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 24. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The accelerated approval of oncologic drugs: lessons from ponatinib.
    Prasad V; Mailankody S
    JAMA; 2014 Jan 22-29; 311(4):353-4. PubMed ID: 24449310
    [No Abstract]   [Full Text] [Related]  

  • 26. Accelerated approvals hit the target in precision oncology.
    Subbiah V; Wirth LJ; Kurzrock R; Pazdur R; Beaver JA; Singh H; Mehta GU
    Nat Med; 2022 Oct; 28(10):1976-1979. PubMed ID: 36192554
    [No Abstract]   [Full Text] [Related]  

  • 27. Meaningful endpoints for therapies approved for hematologic malignancies.
    Smith BD; DeZern AE; Bastian AW; Durie BGM
    Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Oncology Center of Excellence Review Processes and Tools.
    Gao JJ; Kluetz PG; Pazdur R
    Clin Pharmacol Ther; 2020 Sep; 108(3):428-429. PubMed ID: 32654129
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA accelerated approval benefits glioblastoma.
    Cloughesy T
    Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
    [No Abstract]   [Full Text] [Related]  

  • 30. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020).
    Ribeiro TB; Bennett CL; Colunga-Lozano LE; Araujo APV; Hozo I; Djulbegovic B
    J Clin Epidemiol; 2023 Jul; 159():151-158. PubMed ID: 37037322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
    Gyawali B; Rome BN; Kesselheim AS
    BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
    Hilal T; Gonzalez-Velez M; Prasad V
    JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
    Herder M
    J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2023 FDA approvals.
    Mullard A
    Nat Rev Drug Discov; 2024 Feb; 23(2):88-95. PubMed ID: 38168801
    [No Abstract]   [Full Text] [Related]  

  • 36. 2022 FDA approvals.
    Mullard A
    Nat Rev Drug Discov; 2023 Feb; 22(2):83-88. PubMed ID: 36596858
    [No Abstract]   [Full Text] [Related]  

  • 37. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US Food and Drug Administration regulatory updates in neuro-oncology.
    Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
    J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
    Miljkovic MD; Tuia JE; Olivier T; Haslam A; Prasad V
    JAMA Intern Med; 2022 Dec; 182(12):1319-1320. PubMed ID: 36315136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.